7 alpha-hydroxy-4-cholesten-3-one and Non-alcoholic Fatty Liver Disease

7 alpha-hydroxy-4-cholesten-3-one has been researched along with Non-alcoholic Fatty Liver Disease in 4 studies

*Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION. [MeSH]

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Aithal, GP; Freilich, B; Hassanein, T; Herring, R; Kayali, Z; Lee, HM; Mantry, P; Newsome, PN; Palmer, M; Sarles, H; Sheikh, A; Sheikh, MY	1
Acevedo, L; Dorenbaum, A; Gedulin, B; Keller, BT; Kennedy, CA; Levin, N; Palmer, M; Tiessen, RG; van Vliet, AA	1
Abdelmalek, MF; Connelly, MA; DePaoli, AM; Harrison, SA; Jaros, MJ; Ling, L; Paredes, AH; Rinella, ME; Rossi, SJ; Trotter, JF	1
Appleby, RN; Khan, S; Manousou, P; Moghul, I; Neal, TD; Walters, JRF; Yee, M	1

Trials

3 trial(s) available for 7 alpha-hydroxy-4-cholesten-3-one and Non-alcoholic Fatty Liver Disease

Article	Year
Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. Journal of hepatology, 2020, Volume: 73, Issue:2 Topics: Alanine Transaminase; Benzothiepins; Biomarkers; Cholestenones; Cholesterol; Double-Blind Method; Female; Glycosides; Humans; Lipid Regulating Agents; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Organic Anion Transporters, Sodium-Dependent; Patient Acuity; Symporters; Treatment Outcome	2020
Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial. BMC gastroenterology, 2018, Jan-05, Volume: 18, Issue:1 Topics: Adolescent; Adult; Aged; Benzothiepins; Bile Acids and Salts; Blood Glucose; Cholestenones; Diabetes Mellitus, Type 2; Double-Blind Method; Feces; Female; Glycosides; Homeostasis; Humans; Lipid Metabolism; Male; Membrane Glycoproteins; Middle Aged; Non-alcoholic Fatty Liver Disease; Organic Anion Transporters, Sodium-Dependent; Symporters; Young Adult	2018
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. Journal of hepatology, 2019, Volume: 70, Issue:4 Topics: Adult; Anticholesteremic Agents; Biomarkers; Biopsy; Cholestenones; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fibroblast Growth Factors; Humans; Lipoproteins, VLDL; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Rosuvastatin Calcium; Treatment Outcome; Triglycerides	2019

Other Studies

1 other study(ies) available for 7 alpha-hydroxy-4-cholesten-3-one and Non-alcoholic Fatty Liver Disease

Article	Year
Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. PloS one, 2019, Volume: 14, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Bile Acids and Salts; Cholestenones; Diarrhea; Female; Fibroblast Growth Factors; Fibrosis; Humans; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Severity of Illness Index; Young Adult	2019

Article

Year

Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study.

PloS one, 2019, Volume: 14, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Bile Acids and Salts; Cholestenones; Diarrhea; Female; Fibroblast Growth Factors; Fibrosis; Humans; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Severity of Illness Index; Young Adult

2019